TEMENOS
6.9.2022 11:56:34 CEST | Business Wire | Press release
Temenos (SIX: TEMN) today announced that it has been recognized as a leader in The Forrester Wave™: Digital Banking Processing Platforms for Corporate Banking, Q3 2022. Temenos believes that its position as a leader reflects the advances in Temenos open platform for composable banking and the broad set of banking services that cover all areas of corporate banking. According to the Forrester report, “Temenos sets the pace in AI-powered banking capabilities and application architecture”. Temenos was also named a Leader in The Forrester Wave™: Digital Banking Processing Platforms for Retail Banking, Q3 2022 evaluation.
The corporate banking report, authored by Jost Hoppermann, Vice President and Principal Analyst, Forrester, notes: “The vendor’s [Temenos’] strategy shows no weak spots. […] The [Temenos] product roadmap includes the continuation of an overarching corporate banking rejuvenation program, AI-powered operations, and fine-grain banking services out of the cloud that are aligned with the concept of a lean core.” The report also states, “Its reference customers reported that the system is very modular, could satisfy almost any needs or requirements, and allows a bank to differentiate.”
This Forrester Wave™ evaluates the top 7 corporate banking platform vendors against 33 criteria, according to their current offering, strategy and market presence. Temenos received the highest score in the strategy category and the 2nd highest score in the current offering category, which Temenos believes reflects its success in serving clients of all tiers to deliver corporate banking services such as Commerce Bank, Bank of Queensland, and Shanghai Commercial & Savings Bank (SCSB).
Max Chuard, Chief Executive Officer, Temenos, said: “We are proud to be recognized as a leader in the Forrester Wave report for corporate banking. Banks have a renewed focus on corporate growth and are seeking more agile, progressive renovation, targeting quicker gains at lower risk and cost – enabled by SaaS, microservices, and packaged banking capabilities. We believe this recognition as a leader by Forrester shows the maturity of our open platform for composable banking and market adoption. Helping clients of all sizes to reduce total cost of ownership, deliver higher service levels with reduced turnaround times and capture new revenue opportunities.”
According to the Forrester report on corporate banking: “Examples of the [Temenos] DBPP’s broad and rich capabilities include functionally rich AI-powered banking capabilities with a strong focus on explainable AI and a state-of-the-art application architecture that has been designed from the ground up to offer choice to banks.”
Temenos was also recently named a ‘Global Power Seller’ and ‘Top Global Player’ based on Forrester’s Global Banking Platform Deals Survey 2022 in the report, ‘Identify The Winners In A Consolidating Banking Platform Market To Make Informed Transformation Decisions.’
With Temenos’ open platform, clients can compose solutions based on granular banking capabilities across all areas of corporate banking including corporate lending, trade finance, payments and cash and liquidity management, with the addition of embedded analytics and compliance. It offers pre-composed, front-to-back solutions and clients and partners can create customized banking services themselves using a personalized sandbox. All these can be integrated with third-party solutions on Temenos Exchange, an ecosystem of pre-integrated fintech solutions. The platform is cloud-native and cloud-agnostic, offering the flexibility to run on-premise, on any private or public cloud, or as SaaS through the Temenos Banking Cloud.
– Ends –
About Temenos
Temenos (SIX: TEMN) is the world’s leading open platform for composable banking, creating opportunities for over 1.2 billion people around the world every day. We serve over 3000 banks from the largest to challengers and community banks in 150+ countries by helping them build new banking services and state-of-the-art customer experiences. The Temenos open platform helps our top-performing clients achieve return on equity three times the industry average and cost-to-income ratios half the industry average.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005567/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom